Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682088 | 0.84 | ESR1 (0.49) | LMNASTSHTR2B | |
| SCHEMBL6260842 | 0.84 | ESR1 (0.49) | LMNASTSHTR2B | |
| SCHEMBL23950970 | 0.72 | CYP3A4 (0.33) | SRD5A1 | |
| 3Alpha-Hydroxy-4,4-Bisnor-8,11,13-Podocarpatriene SCHEMBL12998486 | 0.72 | LMNA (0.57) | SRD5A1LMNATDP1NR1H2NR1H3 | |
| 3Alpha-Hydroxy-4,4-Bisnor-8,11,13-Podocarpatriene SCHEMBL5527834 | 0.72 | LMNA (0.57) | SRD5A1LMNATDP1NR1H2NR1H3 | |
| SCHEMBL5682532 | 0.70 | SHBG (0.48) | LMNASTSHTR2B | |
| SCHEMBL7213779 | 0.70 | SRD5A1 (0.40) | SRD5A1LMNATDP1NR1H2NR1H3 | |
| SCHEMBL8518161 | 0.70 | SHBG (0.48) | LMNASTSHTR2B | |
| SCHEMBL5682603 | 0.70 | SHBG (0.48) | LMNASTSHTR2B | |
| SCHEMBL26237102 | 0.69 | SRD5A1 (0.46) | SRD5A1LMNATDP1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365768-B1 | USE OF ER-BETA SELECTIVE ANTAGONISTS AS CONTRACEPTIVES | BAYER SCHERING PHARMA AG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-6794409-B2 | HOMOSTEROIDS SUCH AS 17-CHLORO-17A-ALPHA-ETHINYL-17A, 18A-DIHOMO-ESTRA-1,3,5(10),16-TETRAENE-3,17A BETA-DIOL; WITHOUT USE OF PROGESTIN; CONTRACEPTION; FOR TREATMENT OF PROLIFERATIVE DISEASES OF THE OVARY | SCHERING AG (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESRRB, ESR2 | SRD5A1 84/4885LMNA 4408/4885TDP1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.